BPC 157 reversed failed healing of 2-week-old vesicovaginal fistulas in rats, stopping urinary leakage within one week and preventing bladder stone formation at both microgram and nanogram doses.
5x bladder capacity restoredBPC 157-treated rats held five times more volume before leaking than healthy rats, with complete fistula closure and zero bladder stones
What the researchers found
BPC 157 therapy initiated 2 weeks after fistula creation (when healing had failed) reversed the course within 1 week across all regimens (10 µg/kg and 10 ng/kg, IP or oral). All treated rats showed: cessation of urinary leakage through vagina, increased epithelization, collagenization, granulation tissue and neovascularization, decreased inflammation and necrosis. By study end (day 56), treated rats exhibited 5x larger bladder volume capacity before leaking compared to healthy controls, complete vesical and vaginal defect closure, and zero stone formation — versus persistent fistulas and stone formation in untreated controls.
Why it matters
Vesicovaginal fistulas affect millions of women worldwide, particularly in developing countries where surgical repair access is limited. A non-surgical treatment that could heal established fistulas — even when started after healing has failed — would be transformative. BPC 157's effectiveness at nanogram doses and via oral administration makes it potentially practical for resource-limited settings.
The numbers in context
Treatment delay: 2 weeks; healing within 1 week; 5x bladder capacity; effective at 10 µg/kg and 10 ng/kg; zero stones in treated rats
How the study worked
Rats received surgically created vesicovaginal fistulas (4 mm bilateral defects). After 2 weeks confirming failed healing, BPC 157 therapy began at two doses (10 µg/kg and 10 ng/kg) via daily intraperitoneal injection or oral administration in drinking water. Healing was assessed at 1, 2, 4, and 6 weeks post-treatment initiation through macroscopic examination, histological analysis (epithelization, collagenization, granulation, neovascularization, inflammation, necrosis), functional testing (volume capacity), and stone formation assessment.
Who was studied
Rats with surgically created vesicovaginal fistulas, treated starting 2 weeks post-injury
What this study cannot tell us
This is an animal study in rats, whose anatomy and fistula healing biology differ significantly from humans. The study was not blinded, introducing potential assessment bias. The fistulas were surgically created under controlled conditions, unlike the complex etiology of human vesicovaginal fistulas (usually from prolonged labor or surgery). No human trials exist for BPC 157 in any fistula indication. The research comes from a single laboratory group that has published extensively on BPC 157.
How to read the evidence
This is a preclinical rat study from a laboratory group that has published extensively on BPC 157. While the results are striking, the non-blinded design, single-laboratory origin, and lack of any human validation limit the evidence strength. The consistency across doses and routes is a positive signal.
When this study was published
Published in 2021, this study adds to over two decades of BPC 157 animal research, all of which remains without human clinical trial validation.
The bigger picture
BPC 157 continues to demonstrate remarkable tissue repair capabilities across a growing list of preclinical fistula and wound models. The vesicovaginal fistula result is consistent with its previously demonstrated healing of gastrointestinal, esophagocutaneous, and other fistula types. The consistency of effects across different tissues, doses, and routes of administration adds to the body of evidence, though the lack of any human clinical trials remains a critical gap.
Questions still open
- Will BPC 157's fistula healing effects translate to human vesicovaginal fistulas, which have different causes and more complex pathology?
- What is the mechanism by which BPC 157 simultaneously promotes tissue healing and prevents stone formation?
- When will randomized human trials of BPC 157 for any tissue repair indication be conducted?
Common questions
What is a vesicovaginal fistula and why is it important?
Why is it significant that BPC 157 worked even when treatment was delayed?
Read the original research
Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats.
Biomedicines, 9(9)
Citation
Rasic, Domagoj; Zenko Sever, Anita; Rasic, Fran; Strbe, Sanja; Rasic, Zarko; Djuzel, Antonija; Duplancic, Bozidar; Boban Blagaic, Alenka; Skrtic, Anita; Seiwerth, Sven; Sikiric, Predrag; Sever, Marko. (2021). Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats.. Biomedicines, 9(9). https://doi.org/10.3390/biomedicines9091206